HUMA
Humacyte, Inc.
Healthcare · Biotechnology · NMS
$1.35
Data: 2026-05-15
✓ ETHICAL PASS

MOAT
MODERATE
Data Confidence: 71.4%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$207M
Total market value of the company
Trailing P/E
N/A
Forward P/E
-3.39
Based on estimated future earnings — lower means cheaper
Rev Growth
-4.3%
Year-over-year revenue change
Profit Margin
N/A
How much profit the company keeps from each dollar of revenue
ROE
-409.5%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$5.58
+314% from current price — median analyst estimate
Recommendation
BUY
Consensus view from 6 analysts covering this stock
About Humacyte, Inc.

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

https://www.humacyte.com

Country: United States Employees: 184 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
26.0% PASS
Debt must be below 33% of total assets
Cash Ratio
20.1% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKUP
Price trending up with increasing momentum
Sharpe Ratio
-0.288
Returns do not compensate for the risk — negative edge
Kelly Fraction
-0.0430
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.658
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-61.8%
Historical annualised return based on price data
Max Drawdown
-93.9%
Largest peak-to-trough decline — the worst it has been
HMM State
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
9
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
2.31
Significantly more volatile than the market
52W High
$2.93
54% below the year high
52W Low
$0.55
147% above the year low
Avg Volume
6,915,011
Average daily shares traded — higher means easier to buy and sell
Short Ratio
8.5
Days it would take all short sellers to cover — higher means more crowded
Short % Float
20.3%
Very high short interest — potential squeeze candidate
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.26
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
5.72
Heavy leverage — higher financial risk if revenues decline
Current Ratio
3.93
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
3.03
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
-5,704.0%
Profit from core operations before interest and tax
Free Cash Flow
$-64,806,624
Negative — the business is spending more than it generates
Revenue (TTM)
$2M
Total revenue over the last 12 months
Net Income
$-95,217,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
6
Target High
$25.00
Target Median
$5.58
Target Low
$1.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-05-19 SEBELIUS KATHLEEN G Director 56,818 $50,000
2026-05-18 PARIKH SHAMIK J Officer 45,887 $41,147
2026-05-18 SANDER DALE A Chief Financial Officer 45,887 $41,147
2026-05-18 CONSTANTINO MICHAEL T Director 11,000 $9,840
2025-11-14 SANDER DALE A Chief Financial Officer 311,100 —
2025-11-14 PARIKH SHAMIK J Officer 311,100 —
2025-08-20 NIKLASON LAURA E Chief Executive Officer 2,241,045 $3,733,191
2025-08-20 DOUGAN BRADY W Director 2,241,045 $3,733,191
2025-04-14 SCHEESSELE WILLIAM JOHN Officer 6,493 $9,999
2025-04-10 SANDER DALE A Chief Financial Officer 20,000 $30,600
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Political Trading Activity

Congressional trading disclosures involving this instrument

Date Politician Party Type Amount
2026-04-13 Ro Khanna Democrat Purchase 1K–15K
Source: Congressional disclosure filings. View all political trades at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.